We are a clinical-stage biopharmaceutical company developing targeted molecular therapies for cancer.
We are developing molecular therapies that control universal cancer pathways to unlock the unrealized potential of targeted cancer therapies, such as tyrosine kinase inhibitory drugs (TKIs).
Our tumor suppression technologies are pan-kinase inhibitors that work to induce apoptosis (programmed cell death) in cancer cells and to control cell signaling and inflammatory pathways to treat cancer at the molecular level. Our discoveries and R&D programs have been the subject of more than 30 peer-reviewed publications and have been supported by more than $45 million from investigator grant awards and corporate funding. We control a portfolio of 16 issued and 9 pending patents covering tumor suppressors, therapeutics, diagnostics, nanovesicle delivery systems and manufacturing processes.
Oncoprex®, our lead product candidate, regulates the activation of multiple oncogenic kinases and has shown synergistic anti-cancer activity when combined with a number of kinase inhibitor drugs (KIs). Oncoprex is expected to participate in major oncology markets in combination with KIs.
GPRX203, our second product candidate, is in advanced preclinical development for combination use with platinum drugs for solid tumor indications.